The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Aveo; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Merck Serono; Pfizer; Pfizer/Astellas; Sanofi/Aventis
Speakers' Bureau - Astellas Pharma; Bayer; Exelixis
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Randy F. Sweis
Stock and Other Ownership Interests - Abbvie (I)
Honoraria - AVEO
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Loxo/Lilly; Pfizer; Seattle Genetics/Astellas
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Eisai (Inst); EpiVax Oncology (Inst); Genentech (Inst); Immunocore (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pionyr (Inst); Pyxis (Inst); QED Therapeutics (Inst); Scholar Rock (Inst)
Patents, Royalties, Other Intellectual Property - Neoantigens in Cancer, PCT/US2020/031357
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Astellas Pharma; AVEO; Exelixis; Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen
 
Ahmad A. Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Leadership - AI Proteins, Inc
Stock and Other Ownership Interests - AI Proteins, Inc; Ironwood Pharmaceuticals (I)
Honoraria - BeiGene; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Amgen; Arcus Biosciences; Array BioPharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Ellipses Pharma; EMD Serono; Genentech; Gilead Sciences; InterVenn Biosciences; ITeos Therapeutics; Jounce Therapeutics; Karyopharm Therapeutics; Lilly; Mariana Oncology; Merck; Merus; Mirati Therapeutics; Moderna Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Sanofi; Silverback Therapeutics; Takeda; Tempus
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis; Novartis (Inst); Palleon Pharmaceuticals (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - Grand Rounds in Urology; Ideology Health; Onviv; PeerView; PrecisCa; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Kura Oncology; Loxo/Lilly; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Astellas Pharma; AVEO; Bayer; Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Janssen Oncology; Medscape; Merck; Natera; Pfizer; Research to Practice; Seagen
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb
Other Relationship - Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
David J. Park
Honoraria - AstraZeneca; XBiotech
Consulting or Advisory Role - AstraZeneca; Novocure
Speakers' Bureau - AstraZeneca; Caris MPI
Research Funding - Astellas Pharma; BeiGene; Biorasi; Curium Pharma; Daiichi Sankyo/Astra Zeneca; La Nova; Merck; Novartis; Roche/Genentech
 
Sunil Babu
Employment - Fort Wayne Medical Oncology & Hematology
Leadership - Exigent Research
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology; Lutheran hospital (I)
Honoraria - Cornerstone Healthcare Group; Janssen Scientific Affairs; Novartis; Pfizer
Consulting or Advisory Role - Cornerstone Specialty Network; E.R. Squibb Sons, LLC; Kite, a Gilead company; Novartis; Taiho Oncology
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Aptose Biosciences (Inst); Aptose Biosciences (Inst); argenx (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Scholar Rock (Inst); Syndax (Inst); Takeda (Inst); TG Therapeutics (Inst); Torl Biotherapeutics (Inst)
Travel, Accommodations, Expenses - BeiGene; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics
 
Yawen Ju
No Relationships to Disclose
 
Lan Liu
No Relationships to Disclose
 
Susan Henry
No Relationships to Disclose
 
Lu Gan
No Relationships to Disclose
 
Timothy A. Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Blueprint Medicines; Boxer; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; ProLynx; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tango Therapeutics; Tesaro (Inst); Vivace Therapeutics (Inst); Zenith Epigenetics (Inst)